Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 20;24(3):2079.
doi: 10.3390/ijms24032079.

Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives

Ivan Melnikov  1   2 , Sergey Kozlov  1 , Olga Saburova  1 , Yuliya Avtaeva  1 , Konstantin Guria  1 , Zufar Gabbasov  1
Affiliations
Review

Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives

Ivan Melnikov et al. Int J Mol Sci. .

Abstract

This review aimed to trace the inflammatory pathway from the NLRP3 inflammasome to monomeric C-reactive protein (mCRP) in atherosclerotic cardiovascular disease. CRP is the final product of the interleukin (IL)-1β/IL-6/CRP axis. Its monomeric form can be produced at sites of local inflammation through the dissociation of pentameric CRP and, to some extent, local synthesis. mCRP has a distinct proinflammatory profile. In vitro and animal-model studies have suggested a role for mCRP in: platelet activation, adhesion, and aggregation; endothelial activation; leukocyte recruitment and polarization; foam-cell formation; and neovascularization. mCRP has been shown to deposit in atherosclerotic plaques and damaged tissues. In recent years, the first published papers have reported the development and application of mCRP assays. Principally, these studies demonstrated the feasibility of measuring mCRP levels. With recent advances in detection techniques and the introduction of first assays, mCRP-level measurement should become more accessible and widely used. To date, anti-inflammatory therapy in atherosclerosis has targeted the NLRP3 inflammasome and upstream links of the IL-1β/IL-6/CRP axis. Large clinical trials have provided sufficient evidence to support this strategy. However, few compounds target CRP. Studies on these agents are limited to animal models or small clinical trials.

Keywords: C-reactive protein; atherosclerosis; biomarker; inflammation; mCRP; monomeric C-reactive protein; residual inflammatory risk; thromboinflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Proposed roles for mCRP in atherosclerosis. mCRP, monomeric C-reactive protein; pCRP, pentameric C-reactive protein; TF, tissue factor; CAM, cell-adhesion molecules; oxLDL, oxidized low-density lipoproteins.
Figure 2
Figure 2
Anti-inflammatory agents targeting the NLRP3 inflammasome and IL-1β/IL-6/CRP axis. Upstream agents targeting the NLRP3 inflammasome, interleukin (IL)-1β, and IL-6 reduce the rate of major adverse cardiovascular events, according to large RCTs. Downstream agents target translation of pCRP in the liver, CRP dissociation, and mCRP. Studies on these agents are limited to animal models and small RCTs. CRP, C-reactive protein; mCRP, monomeric C-reactive protein; pCRP, pentameric C-reactive protein; RCTs, randomized clinical trials.
See this image and copyright information in PMC

References

    1. Ference B.A., Graham I., Tokgozoglu L., Catapano A.L. Impact of Lipids on Cardiovascular Health. J. Am. Coll. Cardiol. 2018;72:1141–1156. doi: 10.1016/j.jacc.2018.06.046. - DOI - PubMed
    1. Robinson J.G., Williams K.J., Gidding S., Borén J., Tabas I., Fisher E.A., Packard C., Pencina M., Fayad Z.A., Mani V., et al. Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. JAHA. 2018;7:e009778. doi: 10.1161/JAHA.118.009778. - DOI - PMC - PubMed
    1. Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., De Backer G.G., Delgado V., Ference B.A., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020;41:111–188. doi: 10.1093/eurheartj/ehz455. - DOI - PubMed
    1. Giugliano R.P., Pedersen T.R., Park J.-G., De Ferrari G.M., Gaciong Z.A., Ceska R., Toth K., Gouni-Berthold I., Lopez-Miranda J., Schiele F., et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390:1962–1971. doi: 10.1016/S0140-6736(17)32290-0. - DOI - PubMed
    1. Schwartz G.G., Gabriel Steg P., Bhatt D.L., Bittner V.A., Diaz R., Goodman S.G., Jukema J.W., Kim Y.-U., Li Q.H., Manvelian G., et al. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score–Matched Analysis of the ODYSSEY OUTCOMES Trial. Circulation. 2021;143:1109–1122. doi: 10.1161/CIRCULATIONAHA.120.049447. - DOI - PMC - PubMed